GSPT1 protein: a key regulatory target of glucose metabolic reprogramming in triple-negative breast cancer

Author: Senior Product Manager of UA Views：13

This article focuses on the specific high expression and glucose metabolism regulatory function of glutathione S-transferase Pi 1 (GSTP1, also referred to as GSPT1 in the text) in triple-negative breast cancer, systematically elaborating the discovery process of its role as a key regulatory factor in glycolysis metabolism in triple-negative breast cancer cells, analyzing the molecular mechanisms by which small-molecule inhibitors targeting this target damage tumor cell growth through inhibiting GAPDH activity and its downstream metabolic pathways and signaling pathways, and discussing the potential value of this target in targeted therapy for triple-negative breast cancer.

Recent Advances
Product Information

Recent Advances

GSPT1 Protein: A Key Regulatory Target of Glucose Metabolic Reprogramming in Triple-Negative Breast Cancer

Summary: This article focuses on the specific high expression and glucose metabolism regulatory function of glutathione S-transferase Pi 1 (GSTP1, also referred to as GSPT1 in the text) in triple-negative breast cancer. It systematically describes the discovery process of GSTP1 as a key regulatory factor of glycolytic metabolism in triple-negative breast cancer cells, analyzes the molecular mechanism by which small-molecule inhibitors targeting this target damage tumor cell growth through inhibition of GAPDH activity and its downstream metabolic pathways and signaling pathways, and discusses the potential value of this target in targeted therapy for triple-negative breast cancer.

I. Metabolic Reprogramming Characteristics and Therapeutic Dilemmas of Triple-Negative Breast Cancer.

Breast cancer can alter metabolic pathways to drive pathogenesis, and due to its drug resistance, conventional chemotherapy does not achieve good efficacy. Triple-negative breast cancer, as a subtype lacking expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, is insensitive to endocrine therapy and targeted therapy against human epidermal growth factor receptor 2; chemotherapy remains its main systemic treatment modality, and the emergence of drug resistance further narrows the therapeutic window. Against this background, the metabolic reprogramming that tumor cells undergo to meet the material and energy demands of rapid proliferation has become an important direction for identifying new therapeutic targets. Abnormal activation of glucose metabolism, particularly the glycolytic pathway, is one of the key metabolic features by which triple-negative breast cancer cells maintain rapid proliferation, and it also provides a theoretical basis for precise intervention targeting metabolic enzymes.

II. Specific High Expression of GSTP1 in Triple-Negative Breast Cancer and Target Discovery.

Using a chemical proteomics research platform, researchers systematically compared the expression profiles of metabolic enzymes across different breast cancer cell lines and found that, compared with other breast cancer cells, GSTP1 is specifically highly expressed only in triple-negative breast cancer cell lines. Researchers further found that this metabolic enzyme, specifically highly expressed in triple-negative breast cancer, is crucial for glucose metabolism in triple-negative breast cancer tumor cells. GSTP1 regulates glycolytic metabolism in tumor cells and can serve as a new target. From the perspective of target discovery logic, the value of this finding is reflected at two levels: first, the expression of GSTP1 is subtype-specific, being significantly enriched in triple-negative breast cancer cells while expressed at lower levels in other breast cancer subtypes, providing a molecular basis for selective intervention; second, GSTP1 is not merely a detoxification enzyme but carries a non-canonical function in tumor cells of regulating glycolytic metabolism, and this functional positioning makes it a key node connecting metabolic reprogramming and tumor growth.

III. Molecular Mechanism by Which GSTP1 Inhibition Damages the Growth of Triple-Negative Breast Cancer Cells.

At the mechanistic level, when GSTP1 is inhibited, the growth of triple-negative breast cancer cells is damaged through inhibition of GAPDH activity and its downstream metabolic pathways and signaling pathways. GAPDH is a key enzyme in the glycolytic pathway, catalyzing the conversion of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate, and its activity directly determines the level of glycolytic flux. The regulation of GAPDH activity by GSTP1 places this target upstream in the control of glycolytic flux——inhibiting GSTP1 not only reduces the catalytic activity of GAPDH but also, through the连锁 effects of downstream metabolic pathways and changes in signaling pathways, jointly constitutes multi-level damage to tumor cell growth. This “one target, multiple effects” mode of action gives GSTP1 inhibition an advantage over directly targeting a single metabolic step, as it is more difficult to compensate for.

IV. Validation of Antitumor Efficacy in In Vitro and In Vivo Models.

In in vitro cytological experiments, the compound showed good inhibitory effects on the triple-negative breast cancer cell line 231MFP cells. In in vivo nude mouse models, the compound likewise demonstrated good inhibitory effects on tumors derived from 231MFP cells. The consistency between in vitro and in vivo results is important evidence that this target and its inhibitors have translational potential——in vitro experiments confirmed the direct effect of the compound on tumor cells, while in vivo experiments further verified that this effect can be maintained in a complex biological environment, excluding the common risk that in vitro activity cannot be translated into in vivo efficacy. The research results were recently published in Cell Chemical Biology, and their academic value lies in integrating subtype-specific expression of metabolic enzymes, regulation of glycolytic flux, and targeted small-molecule intervention into a complete evidence chain.

VI. Conclusion.

As a metabolic enzyme that is specifically highly expressed in triple-negative breast cancer cells and crucial for glucose metabolism, GSTP1, by virtue of its subtype-specific expression characteristics identified through a chemical proteomics platform, its core function of regulating glycolytic metabolism in tumor cells, its druggability validated through targeting by the small-molecule inhibitor LAS-17, and its molecular mechanism of damaging tumor cell growth through inhibition of GAPDH activity and its downstream metabolic pathways and signaling pathways, has become a highly promising new target in the field of metabolic targeted therapy for triple-negative breast cancer. From chemical proteomics screening to inhibitor design, and from in vitro cytological validation to antitumor efficacy in in vivo nude mouse models, GSTP1 continues to drive the in-depth development of the field of precision therapy for triple-negative breast cancer.

In GSTP1-related basic research and drug development, high-quality recombinant GSTP1 protein is a core tool for elucidating the mechanism of its interaction with GAPDH, evaluating the binding activity of small-molecule inhibitors, and conducting enzymatic function studies. The GST tag facilitates efficient purification through glutathione affinity chromatography and can also serve as a detection tag for analyses such as enzyme-linked immunosorbent assay and surface plasmon resonance. To meet the needs of GSTP1 functional research and targeted therapy development for triple-negative breast cancer, Uai provides GSPT1 GST tag Protein, Human. This product is suitable for applications including in vitro studies of the interaction between GSTP1 and GAPDH and the mechanism by which it regulates GAPDH activity, binding activity analysis and screening evaluation of GSTP1-targeted small-molecule inhibitors, exploration of the mechanism of GSTP1-mediated regulation of glycolytic metabolism, and development of metabolic targeted therapeutic strategies for triple-negative breast cancer.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next